Neuroendocrine Tumours
Ariceum Therapeutics GmbH focuses on somatostatin receptor positive neuroendocrine tumours, with clinical interest centred on disease populations defined by receptor expression and long-term treatment follow-up.
- Somatostatin receptor positive NETs
- Neuroendocrine oncology
- Receptor-targeted cancer care
The sponsor’s research activity in this area is directed toward clinical monitoring of patients with neuroendocrine tumours, reflecting involvement in specialised oncology settings.
Long-term Safety in Oncology
Its clinical research includes evaluation of long-term safety in previously treated participants, with attention to later-occurring health outcomes in oncology populations.
- Safety surveillance
- Late adverse outcomes
- Secondary malignancy monitoring
Particular interest is placed on the occurrence of second primary malignancies, covering both haematological and non-haematological cancers.
Haematological Malignancies
The sponsor’s research landscape extends to the detection and assessment of blood cancers arising after prior cancer treatment, with emphasis on ongoing oncological risk evaluation.
- Haematological cancer surveillance
- Secondary blood malignancies
- Oncology follow-up care
This area reflects a focus on understanding malignancy patterns relevant to patients with prior exposure to specialised cancer therapies.
Non-haematological Cancer Monitoring
Ariceum Therapeutics also shows interest in solid tumour surveillance within the context of long-term cancer follow-up, particularly for new malignancies distinct from the original disease.
- Secondary solid tumours
- Non-haematological oncology
- Post-treatment cancer monitoring
The clinical focus includes tracking broader oncological outcomes in participants with a history of targeted treatment for neuroendocrine tumours.
